



Table of content

Number	Title	Page Number
Appendix Figure S1	MSCs depict reduced suppression of NET formation in the presence of LPS in co-cultures with neutrophils.	2
Appendix Figure S2	Both non-primed MSCs and LPS primed MSCs suppress T cell proliferation in a mixed lymphocyte reaction.	3
Appendix Figure S3	No significant difference in β2M+ MSC numbers in wounds injected with non-primed versus LPS-primed MSCs.	4
Appendix Figure S4	LPS stimulation reveals repressed stimulation of CXCL6/IL-1β/IL-8 expression in TLR4 silenced MSCs.	5
Appendix Figure S5	MSCs fulfill minimal criteria of stem cells.	6-7
Appendix Table S1	RNAseq analysis: Top up and down regulated genes in MSCs following 6h and 24h of LPS stimulation.	8
Appendix Table S2	Primers List.	9

Appendix Figure S1




Appendix Figure S1. MSCs depict reduced suppression of NET formation in the presence of LPS in co-cultures with neutrophils.

A PMA activated neutrophils were co-cultured with MSCs in the presence of LPS at a concentration of 100 ng (lower row, right panel). No difference in the attenuated suppression of NET formation was observed compared to PMA activated neutrophils co-cultured with LPS primed MSCs (lower row, left panel). Non-primed MSCs, by contrast, led to a significantly stronger suppression of NET formation (upper row, outer right panel). Incubation of neutrophils with PMA alone served as positive control and DMSO treated neutrophils as negative control. Scale bars: 50µm. A representative experiment out of 3 independent experiments is depicted.

B Quantification of NET bound elastase indicative of NET formation. Statistical analysis was performed using one way ANOVA, values are represented as mean ± SEM, n=3 biological replicates.


Appendix Figure S2



Appendix Figure S2. Both non-primed MSCs and LPS primed MSCs suppress T cell proliferation in a mixed lymphocyte reaction.

CFSE labeled PBMCs from buffy coat of healthy, unrelated, non-HLA-matched donor (effector cells A) were stimulated with irradiated PBMCs (stimulator cells B) in the absence or presence of untreated or LPS-treated MSCs. After 7 days, cells were stained for CD2 and 7-AAD. Live cells were identified by 7-AAD negativity and proliferation of CD2⁺ T cells was defined by CFSE dilution. Statistical analysis was performed using one way ANOVA, values are represented as mean ± SEM, n=6 biological replicates.


Appendix Figure S3



Appendix Figure S3. No significant difference in $\beta 2M^{+}$ MSC numbers in wounds injected with non-primed versus LPS-primed MSCs.

Quantification of human $\beta 2M^{+}$ MSCs in the skin wounds that were treated either with PBS or LPS primed MSCs for 24h. Counting of $\beta 2M^{+}$ MSCs in wound sections was performed 24h after the administration of MSCs. Statistical analysis was performed using unpaired t-test, values are represented as mean \pm SEM, n=6 biological replicates. ns, non-significant.





Appendix Figure S4



Appendix Figure S4. LPS stimulation reveals repressed stimulation of CXCL6/IL-1β/IL-8 expression in TLR4 silenced MSCs.

qPCR results demonstrating mRNA expression of CXCL6, IL-1β and IL-8 upon silencing of TLR4 in LPS-primed silenced MSCs. Comparisons were made between 'Scr MSCs vs Scr MSCs + LPS', 'Scr MSCs vs TLR4 Si MSCs + LPS', and 'Scr MSCs + LPS vs TLR4 Si MSCs + LPS'. Statistical analysis was performed using one way ANOVA, values are represented as mean ± SEM, n=3 biological replicates.

Appendix Figure S5



Appendix Figure S5. MSCs fulfill minimal criteria of stem cells.

- A Flow cytometric analysis of cell surface marker expression on MSCs, including CD105, CD73, CD71, CD45, CD31, and HLA-ABC. Marker-specific antibodies labelled MSCs were shown in filled histograms, and the isotype control antibodies labelled cells were shown in empty histograms. They express typical MSC markers including CD73, CD90, CD105, and CD71 and do not express the leukocyte marker CD45, or endothelial marker CD31. They are MHC class I positive. MSCs in culture are plastic adherent.
- B-D MSCs were cultured in adipogenic, osteogenic and chondrogenic induction media and subjected to Oil-Red-O staining indicative of adipogenic differentiation, Alizarin Red-S staining indicative of osteogenic differentiation and aggrecan staining indicative of chondrogenic differentiation. Scale bar: 50 μ m.

Appendix Table S1

0 vs 6h LPS

Genes	0 vs 6 hr Up	Genes	0 vs 6 hr Down
SOX6	5366,999	FAM83H	-365,784
CACNG8	2223,166	MIR137,MIR137	
CTC1	187,8022	HG	-224,908
RSAD2	116,326	EP300	-212,861
OAS1	111,9034	LOC101927806	
OASL	106,4853	,TRNAE1	-107,972
IL8	58,24491	C7orf43	-67,9716
CCL5	48,25144	POLM	-41,7484
TMCC3	42,46994	ST8SIA1	-31,1604
PISD	30,51803	IRAK3	-21,7459
GBP4	30,40338	RP11-887P2.5	-13,8905
CCL20	28,83222	RBBP8	-13,7568
C15orf48	28,38211	TEX21P	-13,6169
STS	28,19095	RGS7	-12,6202
MX1	27,33637	MAGED4	-12,1152
TNFSF13B	25,11992	PDCD4	-11,8781
GNA15	24,45487	PGR	-10,86
IL1B	24,25987	ENPP5	-10,5913
CMPK2	23,96339	LOC644662	-10,5909
LOC101929580	22,19034	MIR4292	-10,5909
CSF2	19,82831	RIMBP3	-9,07791
SLC25A15	16,2507	LINC00571	-9,07791
C3	15,86263	TRNAC24	-9,07791
MIR433	15,4309	DLG3-AS1	-9,07684
IFIT1	15,06397	SLITRK6	-8,32142
OAS2	14,10926	KIAA0226	-8,17031
IFIH1	13,50967	MAST1	-7,56521
IFI44L	13,19098	CECR6	-7,56516
MIR423	12,39108	CCNYL2	-7,56495
UBAP2	11,8392	AC016995.3	-7,56495
IFIT2	11,51929	RP3-322G13.5	-7,56495
CXCL6	11,4249	ARGFXP2	-7,56489
LOC101926887	10,71493	MYBPH	-7,45951
CXCL1	10,41622	LOC102723729	-7,37325
GIMAP2	9,914156	INSC	-7,20022
SERPINB2	9,896785	LOC102724423	-6,80847
AQP6	9,890408	LOC100507054	-6,80847
MX2	9,732969	CYP21A2	-6,78905
ICAM1	9,641783	LOC101929149	
C6orf58	9,253185	,LOC10272421	
BATF2	9,152526	8	-6,65321
TNF-SF10	9,116247	VWA8	-6,50207
LOC102723726,		NR113	-6,49208
TNF-AIP2	8,245517	KIAA1456	-6,40336
MEOX1	8,146441	LOC101928051	-6,28089
RNF170	8,095892	LPAR4	-6,22498
IFIT3	8,058102	ATP1A3	-6,05338
ARNT2	8,00183	ACP5	-6,05279
C20orf195	7,945181	ADH4	-6,05208
FLJ45079	7,931315	LOC101928874	-6,05195
ADH1C	7,931315	HNRNPA1P10	-6,05195
		RP11-480I12.7	-6,05195
		RP5-858B6.3	-6,05195
		LOC101930434	-6,05195

0 vs 24h LPS

Genes	0 vs 24 hr Up	Gene	0 vs 24 hr Down
STS	67,3782	FAM83H	-325,33
TBC1D17	49,89488	LOC554223	-278,78
TOMM40L	44,94068	EP300	-181,54
REXO1	33,7176	C10orf118	-138,31
CELSR3	32,59232	MIR137,MIR137	
IL8	19,40074	HG	-73,904
SULT1A1	17,19146	POLM	-34,344
DNAH12	15,61413	LOC101928221	-33,303
CXCL6	15,24834	MAGED4	-20,716
LOC284454	14,569	IRAK3	-19,105
IL1B	13,54567	ILDR2	-17,095
C3	12,87294	KSR2	-13,994
SYNGAP1	11,24296	C5AR1	-13,684
GIMAP2	10,45927	PRRG4	-12,682
FAM172A	9,912988	RP3-322G13.5	-12,429
RNF170	9,636104	RANBP3L	-11,293
GNA15	9,595912	GPR116	-10,628
PCDHA1	9,466689	PDCD4	-10,549
LOC101930071	9,265636	LINC00982	-10,472
RP11-290F20.3	8,889856	TRNAL16	-8,7004
CXCL1	8,864627	RP3-400B16.1	-8,7004
TNFRSF9	8,832672	RIMS4	-8,496
CCL5	8,448294	LOC102723663	-7,8602
SERPINB2	8,242717	TLL1	-7,4645
KCNJ5	8,179598	LINC01160	-7,4575
HES7	8,051793	HIGD2B	-7,4575
LOC101929609	8,0456	LOC644189	-7,4575
LOC100652930	8,0456	TRNAC24	-7,4575
LOC100506974	8,0456	FAM135B	-7,3347
CSF2	8,0456	GABRB3	-6,7794
LOC100499194	8,004881	KIAA1456	-6,5986
TMBIM1	7,75534	P2RX6	-6,2189
CXCL5	7,6943	MAOA	-6,2171
NME5	7,522541	AC016738.3	-6,2146
CAMSAP3	7,244821	TRNAR22	-6,2146
CCL13	7,241055	MIR193A	-6,2146
LOC102723600	7,241055	SNAR-G2	-6,2146
DUSP8,LOC101		MIR6743	-6,2146
927562	7,241055	NAPSA	-6,2146
OR1J2	7,241055	TCP10L	-6,2146
LOC101928549	7,241055	C6orf165	-6,2146
C6orf58	7,241055	RP11-423C15.3	-6,2146
NTF4	7,237693	MIR7845	-6,2146
MED25	6,975081	HCCAT3	-6,2146
C1orf228	6,919079	WNT10B	-6,2146
LHFPL4	6,436471	LOC101928153	-6,2146
LOC102724715	6,436471	LOC101927919	-6,2146
DGCR8	6,332785	C2CD4A	-6,2146
LOC101928841	6,305234	DNAH9	-6,2146
RAPGEF5	6,235132	AC016995.3	-6,2146
FTCD	6,155773	SNORD105B	-6,205

Appendix Table S2

Primers List

Genes (human)	Forward primer	Reverse primer
IL-1 β	AATCTGTACCTGTCTGCGTGTT	TGGGTAATTTTTGGGATCTACACTCT
IL8	ATGACTTCCAAGCTGGCCGTGGCT	TCTCAGCCCTCTTCAAAAATTCTC
CXCL6	AGAGCTGCGTTGCACTTGTT	GCAGTTTACCAATCGTTTTGGGG
MyD88	GACATGGTTAGGCTCCCTCA	GCACATGGGCACATACAGAC
TLR4	CGGAGGCCATTATGCTATGT	TCCCTTCCTCCTTTCCCTA
IL6	AGACAGCCACTCACCTCTTCAG	TTCTGCCAGTGCCTCTTTGCTG
β -actin	TCACCCACACTGTGCCCATCTACGA	CAGCGGAACCGCTCATTGCCAATGG